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Abstract 
BACKGROUND: Oral isotretinoin is an effective therapy for acne. However, isotretinoin can induce 
hyperhomocysteinemia and decreased serum folic acid level, which may be a risk for cardiovascular disease and 
thrombosis, as well as psychoses. Besides, many recent types of research emphasise the safety and effects of 
the low dose isotretinoin therapy.  
AIM: The aim of our study was to evaluate the effect of the low-dose isotretinoin on the plasma homocysteine and 
serum folic acid level in the Vietnamese population.  
METHODS: We conducted a longitudinal study to evaluate the effectiveness of the low-dose therapy on the 
plasma homocysteine and serum folic acid level of 52 acne patients after 6-8-week treatment at University 
Medical Center Ho Chi Minh City, Viet Nam. Patients had moderate-severe acne with the prolonged course, and 
most of them had a scar.  
RESULTS: With a low dose of oral isotretinoin (0.37 ± 0.11 mg/kg/day), after 6-8-week treatment, patients 
dropped the severity of disease, increased the plasma homocysteine level and decreased the serum folic acid 
level with significant differences in comparison to those before treatment. However, these changes do not exceed 
the normal range.  
CONCLUSION: In overall, low dose isotretinoin treatment had effectiveness in decrease the severity of disease 
and no increasing the plasma homocysteine level as well as the serum folic acid level. 
 
 
 
 
Introduction 
 
Acne is a popular skin disease with the 
incidence in adolescence of up to 85-100%, including 
30% moderate and 10% severe acne [1], [2], [3], [4]. 
Isotretinoin has been used to treat moderate-severe 
acne where standard treatment was not effective. 
Compared to other treatments, isotretinoin has been 
shown to be more responsive in decreasing the size 
and secretion of sebaceous gland [5]. However, 
isotretinoin may result in elevated plasma 
homocysteine and decreased serum folic acid which 
in turn contribute to cardiovascular diseases, 
thrombosis, cognitive function disorders and dementia 
[6], [7], [8].  
Many researchers have evaluated which 
isotretinoin dose would have the most efficacy and 
less adverse events. Recent studies indicated the 
safety of the oral isotretinoin therapy where the low 
dose of isotretinoin (< 0.5 mg/kg/day) had no 
significant effects in metabolic disorders [9], [10]. 
Effective treatment and less severe side effects were 
found in a study among 638 patients, both male and 
female, with moderate acne that were treated with 
isotretinoin at 20 mg/d (approximately 0.3-0.4 mg/kg 
per day) for 6 months [9]. Another study among 150 
Malaysian patients treated with isotretinoin at 10mg 
on the daily basis until a cumulative dose of 90-110 
mg/kg showed that after 24 weeks of treatment, all 
patients cleared of acne lesions with a low rate of 
elevated liver enzymes and serum lipid at 3.3% and 
2.7% respectively. There was no case of 
discontinuation in treatment [11]. The 
hyperhomocysteinemia with low serum folic acid level 
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cause many severe side effects, but there was no 
study in the literature about this disorder in low-dose 
isotretinoin therapy. 
Therefore, in this study, we evaluated the 
changes of the homocysteine and folic acid level 
during oral isotretinoin treatment in Vietnamese acne 
patients. Findings from this study might contribute to 
the literature whether we should monitor the plasma 
homocysteine and serum folic acid in patients treated 
with oral low-dose isotretinoin to prevent 
hyperhomocysteinemia, decrease folic acid level and 
possibly related disorders. 
 
 
Methods 
 
Setting and Participants 
In September 2014, a longitudinal study was 
conducted at the Skin Care Department, University 
medical centre HCMC. We recruited 52 acne patients 
above 18 years old. All patients received the 
explanation of objects and procedures and signed the 
consent form. Patients were then treated with oral 
Isotretinoin once a day for 6 – 8 weeks. Those who 
had hepatic/kidney failure or under treatment with 
drugs such as phenytoin, L-dopa, methotrexate, 
theophylline, penicillamine, vitamin B12, vitamin B6, 
acid folic were excluded. All procedures in this study 
were approved by the Ethics Committee at HCMC 
University of Medicine and Pharmacy, Vietnam. 
 
Procedures 
All patients were asked about their medical 
history and examined to assess the skin type and 
acne status by a dermatologist from the Department 
of Dermatology, HCMC University of Medicine and 
Pharmacy. They have then measured the 
concentration of plasma homocysteine and serum 
folic acid level. After 6 – 8 weeks of treatment, 
patients were re-measured the concentration of the 
plasma homocysteine and serum folic acid level as 
well as re-assessed the clinical characteristics and the 
severity of acne. 
 
Measurements 
The plasma homocysteine level was 
measured by a quantitative method, direct 
chemiluminescent immunoassay with the ADVIA 
Centaur machine of Simen. The serum folic acid level 
was quantified by the Architect C16000 machine of 
Abbott using chemiluminescent microparticle 
immunoassay technology. Patient’s history was 
assessed by onset age (< 25 years old and ≥ 25 years 
old) and disease duration (≥ 24 months and < 24 
months). Clinical symptoms of acne are assessed by 
skin types (oily, normal, combined variants), acne 
lesions (papule, pustule, nodule, cyst, opened and 
closed comedones), affected areas (face, chest, back, 
arm) and scar (atrophic + keloid scar, no scar).  
The severity of acne is evaluated using GAGS 
(Global Acne Grading System) of Doshi, Zaheer and 
Stiller. The GAGS considers six locations on the face 
(forehead, cheeks, nose, chin, chest and back). Each 
is derived by multiplying the factors-2 for forehead, 2 
for each cheek, 1 for nose, 1 for chin, 3 for both 
chests and back by the most heavily weighted lesion 
within each region (1 for ≥ one comedone, 2 for ≥ one 
papule, 3 for ≥ one pustule, and 4 for ≥ one nodule).  
The score for each area (local score) is 
calculated using the formula: Local score = Factor × 
Grade (0-4). The global score is the sum of local 
scores, and acne severity is graded using the global 
score. A score of 1-18 is considered mild; 19-30 as 
moderate; 31-38 as severe; and ≥ 39 as very severe. 
The 25th percentile of the mean cumulative 
isotretinoin dose in our research was 18.5 mg/kg. We 
use this cut-off value to compare pre- and 
posttreatment plasma homocysteine levels and serum 
folate levels based on the accumulative dose of 
isotretinoin. 
 
Data analysis 
We described data using frequency and 
percentage for qualitative variables, the mean and 
standard deviation for quantitative variables. 
Association between patients’ characteristics and 
plasma homocysteine and serum folate levels was 
evaluated using t-test. Comparison of mean plasma 
concentrations of plasma homocysteine and folic acid 
before and after treatment was conducted using a 
paired t-test. Type I error was set at 5%. All data 
analysis was done using SPSS 20.0. 
 
 
Results 
 
In 52 acne patients treated with oral 
isotretinoin therapy at University Medical Center, the 
majority was female (80.8%) with the mean age of 22 
years old and the mean weight of 52.77 kg (SD = 8.97 
kg). Almost all patients had oily skin (90.4%), onset 
age under 5 years old (94.2%) and had acne on the 
face (98.1%). Most patients suffered from moderate 
and severe acne and had scars.  
The mean severity of disease evaluated by 
GAGs score was 25.98 ± 6.5 score as shown in Table 
1. 
 
 Van Thanh et al. Efficacy of Oral Low-Dose Isotretinoin in the Treatment of Acne Vulgaris in Vietnam 
_______________________________________________________________________________________________________________________________ 
_______________________________________________________________________________________________________________________________ 
Open Access Maced J Med Sci. 2019 Jan 30; 7(2):279-282.                                                                                                                                                         281 
 
Table 1: Characteristics of acne patients treated with oral 
isotretinoin 
 N (%) Homocysteine (µg/l) Folate (ng/ml) 
  M (SD) p M (SD) p 
Sex Male 10 (19.2) 10.59 (9.94-
11.55) 
0.00
1 
6.72 (1,85) 0.112 
 Female 42 (80.8) 7.69 (6.63-9.20) 8.27 (2,88) 
Onset age ≥ 25 years old 3 (5.8)     
< 25 years old 49 (94.2)     
Duration of 
disease 
≥ 24 months 40 (76.9) 8.79 (2.37) 0.30
0 
7.94 (2.84) 0.860 
< 24 months 12 (23.1) 8.01 (1.97) 8.10 (2.59) 
Skin type Oily  47 (90.4) 8.6 (2.37) 0.98
0 
8.01 (2.74) 0.790 
Other  5 (9.6) 8.64 (1.41) 7.65 (3.32) 
Acne lesion Close comedone 51 (98.1)     
Open 
comedones 
47 (90.4)   
Papule  50 (96.2)   
Pustule  47 (90.4)   
Nodule  39 (75.0)   
Cyst  18 (34.6)   
Affected area Face  51 (98.1)     
Chest  19 (36.5)   
Back  21 (40.4)   
Arm  2 (3.8)   
Scar  Atrophic scar 38 (73.1)     
Keloid  0 (0)   
Atrophic scar + 
keloid  
2 (3.8)   
No scar 12 (23.1)     
Severity of 
acne 
Mild  6 (11.5) 8.4 (2.13) 0.11
4 
9.65 (3.84) 0.086 
Moderate  32 (61.5) 8.17 (2.09) 8.17 (2.49) 
Severe- very 
severe 
14 (27.0) 9.68 (2.57) 6.81 (2.55) 
 
The oral Isotretinoin dose during 6-8-week 
treatment was 0.37 ± 0.11 mg/kg/day; the 
accumulative dose was 14.67 (18.5-21.95) mg/kg. 
After 6-8-week treatment with oral Isotretinoin, the 
severity of acne followed GAGs and serum folate level 
was statistically significantly decreased; plasma 
Homocysteine levels were significantly statistically 
elevated (P < 0.05) as shown in Table 2. 
Table 2: The severity of acne, the plasma homocysteine and 
serum folate levels in patients before and after 6-8 weeks on 
isotretinoin treatment 
 Before treatment After treatment P 
The severity followed GAGs 25.98 ± 6.50 15.56 ± 6.87 < 0.001 
Homocysteine (µg/l) 8.61 ± 2.29 9.23 ± 2.37 0.016 
Male  10.58 ± 1.12 11.42 ± 1.96 0.252 
Female  7.69 (6.63 – 9.20) 8.27 (7.20 – 10.05) 0.018 
Folate (ng/ml) 7.98 ± 2.76 7.16 ± 2.42 0.005 
 
Post-treatment plasma homocysteine and 
serum folic acid were significantly changed compared 
with the initial values in a group of patients with the 
higher mean accumulative dose of isotretinoin (> 18.5 
mg/kg), as shown in Table 3. There were no statistical 
differences in others. 
Table 3: Comparison of pre- and post-treatment plasma 
homocysteine levels and serum folate levels based on 
accumulative dose of isotretinoin 
Accumulative dose ≤ 18.5 mg/kg 
(N = 26) 
> 18.5 mg/kg 
(N = 26) 
Homocysteine Before treatment 8.43 ± 2.54 8.78 ± 2.04 
After treatment 8.79 ± 2.38 9.67 ± 2.31 
p 0.300
 
0.019
 
Folate Before treatment 8.29 ± 2.98 7.66 ± 2.54 
After treatment 7.55 ± 2.50 6.77 ± 2.31 
p 0.110
 
0.012
 
 
 
Discussion 
This was the first Vietnamese study that 
evaluates the effects of low dose isotretinoin on the 
plasma homocysteine and serum folic acid level in 
acne patients. The results showed that the severity of 
disease of patients treated with a mean dose of 
isotretinoin 0.37 ± 0.11 mg/kg/day after 6-8 weeks 
decreased statistically. This demonstrated that the low 
dose oral Isotretinoin therapy is an effective treatment 
in acne. Besides, the plasma homocysteine level 
increased and the serum folic acid level decreased 
with significant differences in comparison to those 
before treatment. However, these changes do not 
exceed the normal range. Our findings were 
consistent with previous studies where low dose 
isotretinoin has been showed to be beneficial in the 
treatment and a decrease in relapse [9], [10], [11]. 
Hence, to minimise the side effects of drugs, the low 
dose isotretinoin should be considered in the 
treatment of acne disease. 
The hyperhomocysteinemia is a risk factor for 
cardiovascular diseases and venous thrombosis and 
also affects negatively on endothelial cells, smooth 
muscle cells in recent reports [6], [7], [8], [12]. The 
hyperhomocysteinemia was also reported in some 
researches in acne patients treated with isotretinoin. 
In these studies, the plasma Homocysteine level 
significantly increased after treated with oral 
isotretinoin (≥ 0.5 mg/kg/day) during 45 days or more 
[13], [14], [15], possibly because the inhibitions of 
cystathionine  synthase, leading to disrupt the 
metabolism of homocysteine [16]. Another possible 
reason could be that the drug decreased the level of 
folic acid and vitamin B12, resulting in rising 
homocysteine level [14]. Our results also indicated 
that the plasma homocysteine level after 6-8 week 
treatment increased significantly in comparison with 
the initial level (8.61 ± 2.29 g/l with 9.23 ± 2.37 g/l). 
However, this plasma homocysteine level after 
treatment did not exceed the normal biologically range 
of the plasma homocysteine level (15 g/l).  
Regarding the level of folic acid, our results 
confirmed the conclusions of previous national 
studies, in which the serum folic acid dropped 
markedly after oral isotretinoin therapy [17], [18], [14]. 
Karadag et al. observed a decrease of serum acid 
folic level during treatment isotretinoin 0.5 mg/kg/day 
for 4 months [14]. In our study, the serum folic acid 
level after 6-8-week treatment was significantly lower 
in comparison with the initial level (7.98 ± 2.76 ng/ml 
with 7.16 ± 2.42 ng/ml). Nevertheless, similarly to the 
changes in homocysteine level, although this 
difference was statistically significant but not clinically 
meaningful because this decreased level was in 
normal range. The deficiency of folic acid may induce 
some disorders such as neuropathy, psychoses and 
dementia. This deficiency also contributes to advance 
homocysteine level, leading to adverse events of 
hyperhomocysteinemia. According to the results, 
there is no risk for folic acid deficiency-induced 
disorders when the low dose isotretinoin is used.  
Generally, the adverse effects of isotretinoin 
depend on dose. In our study, patients treated with 
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the higher mean accumulative dose of isotretinoin had 
more markedly changes of the serum homocysteine 
and folic acid. Consequently, when using of high dose 
or long term of isotretinoin therapy which may 
increase the cumulative dose, it is essential to prevent 
the risk of rising homocysteine or falling folic acid. 
Vitamin intake such as vitamin B12 or folic acid might 
be proved an effective preventive measure against 
some complication due to hyperhomocysteinemia 
[13], [14], [16]. 
This study was subject to several limitations. 
First, the effects of the long-term low dose isotretinoin 
could not be assessed due to the limited followed-up 
period. Second, we could not clarify the changes in 
homocysteine and folic acid due to the hepatic 
dysfunction or effect on a certain enzyme involved by 
the drug in the synthetic process of 2 substances. 
Third, because there was no control group, the 
different effects of high dose and low dose isotretinoin 
on homocysteine and folic acid level were not able to 
describe. Finally, we were only able to sample clients 
from one hospital in HCMC. Thus, it is possible that 
climatic, socio-economic and/or other differences 
existed among clients across different areas and 
settings. In this regard, further studies were needed. 
In conclusion, we found that moderate and 
severe acne patients treated with low dose isotretinoin 
(< 0.5 mg/kg/day) had no change in the homocysteine 
and folic acid level of the blood, which can induce 
adverse events biologically. Therefore, during 
treatment with the low dose isotretinoin, it is 
unessential to monitor the level of homocysteine and 
folic acid. However, when treated with the higher dose 
or for a long-term period, the risk of increasing of the 
plasma homocysteine and decreasing serum folic acid 
level should be considered. 
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